Nothing Special   »   [go: up one dir, main page]

IN2012MN02896A - - Google Patents

Download PDF

Info

Publication number
IN2012MN02896A
IN2012MN02896A IN2896MUN2012A IN2012MN02896A IN 2012MN02896 A IN2012MN02896 A IN 2012MN02896A IN 2896MUN2012 A IN2896MUN2012 A IN 2896MUN2012A IN 2012MN02896 A IN2012MN02896 A IN 2012MN02896A
Authority
IN
India
Prior art keywords
hydroxychloroquine
hcv
disclosed
hepatitis
virus
Prior art date
Application number
Inventor
Philippe Halfon
Original Assignee
Panmed Ltd
Genoscience Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panmed Ltd, Genoscience Pharma Sas filed Critical Panmed Ltd
Publication of IN2012MN02896A publication Critical patent/IN2012MN02896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods of treating a hepatitis C virus (HCV) related disease are described herein  comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. Therapeutically effective amounts of hydroxychloroquine are disclosed which are sufficient to inhibit HCV-induced autophagy in the subject. An anitviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and an antiviral agent are disclosed. Further disclosed are compositions comprising hydroxychloroquine and an antiviral agent  as well as hydroxychloroquine and uses thereof for the treatment of a hepatitis C virus (HCV) related disease.
IN2896MUN2012 2010-06-24 2011-06-23 IN2012MN02896A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35801410P 2010-06-24 2010-06-24
PCT/IB2011/052762 WO2011161644A1 (en) 2010-06-24 2011-06-23 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent

Publications (1)

Publication Number Publication Date
IN2012MN02896A true IN2012MN02896A (en) 2015-06-12

Family

ID=44630083

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2896MUN2012 IN2012MN02896A (en) 2010-06-24 2011-06-23

Country Status (10)

Country Link
US (2) US8987302B2 (en)
EP (1) EP2585065A1 (en)
JP (1) JP2013529627A (en)
CN (1) CN103096891A (en)
AU (1) AU2011268498A1 (en)
BR (1) BR112012033022A2 (en)
CA (1) CA2803093A1 (en)
IN (1) IN2012MN02896A (en)
MX (1) MX2013000242A (en)
WO (1) WO2011161644A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012MN02896A (en) 2010-06-24 2015-06-12 Panmed Ltd
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN103145811B (en) * 2013-03-15 2014-05-07 深圳翰宇药业股份有限公司 Method for synthesizing Alisporivir
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4491236A2 (en) 2016-05-10 2025-01-15 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP4483875A2 (en) 2016-05-10 2025-01-01 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109790143A (en) 2016-05-10 2019-05-21 C4医药公司 The C of amine connection for target protein degradation3Glutarimide degron body
EP4138831A4 (en) * 2020-04-20 2024-05-15 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine
JP7477152B2 (en) 2020-05-12 2024-05-01 国立大学法人 宮崎大学 Agent for preventing the onset, inhibiting the progression or treating HTLV-1-related diseases
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
CN114796126B (en) * 2022-04-02 2023-04-18 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) Hydroxychloroquine sulfate sustained-release microspheres for articular cavity injection and preparation method thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (en) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー Chemically modified protein, its production method and intermediate
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5314894A (en) 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
PT730470E (en) 1993-11-10 2002-08-30 Enzon Inc IMPROVED INTERFERENCE-POLYMER CONJUGATES
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
ITBO20020416A1 (en) * 2002-06-28 2003-12-29 Valpharma Sa USE OF CHLORINE, HYDROXY-CHLORINE AND 4 AMINO-KINOLINIC DERIVATIVES TO OBTAIN A DRUG FOR THERAPY ANTI RETROVIRAL ACTS
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2004273773B2 (en) * 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
CN102816241B (en) 2004-02-09 2015-07-22 人类基因科学公司 Albumin fusion proteins
ES2359925T3 (en) 2004-07-14 2011-05-30 Novartis Ag USE OF A COMBINATION OF CYCLOSPORIN AND PEGILATED INTERFERONS TO TREAT HEPATITIS C (HCV).
WO2006109196A2 (en) 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
WO2006119061A2 (en) 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
BRPI0614205A2 (en) 2005-08-01 2016-11-22 Merck & Co Inc compound, pharmaceutical composition and compound use
WO2010101649A2 (en) * 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
SG182737A1 (en) 2010-01-27 2012-08-30 Pharma Ltd Ab Polyheterocyclic compounds highly potent as hcv inhibitors
IN2012MN02896A (en) 2010-06-24 2015-06-12 Panmed Ltd
EP2635570B1 (en) 2010-11-01 2017-12-13 RFS Pharma, LLC. Novel specific hcv ns3 protease inhibitors
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus

Also Published As

Publication number Publication date
CN103096891A (en) 2013-05-08
BR112012033022A2 (en) 2016-12-20
US8987302B2 (en) 2015-03-24
CA2803093A1 (en) 2011-12-29
JP2013529627A (en) 2013-07-22
MX2013000242A (en) 2014-04-14
US20130202556A1 (en) 2013-08-08
EP2585065A1 (en) 2013-05-01
WO2011161644A1 (en) 2011-12-29
US20130121965A1 (en) 2013-05-16
US8575195B2 (en) 2013-11-05
AU2011268498A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
IN2012MN02896A (en)
MX2012004032A (en) Compounds for the treatment of hepatitis c.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
MX2013003634A (en) Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases.
MX2009009473A (en) Compounds for the treatment of hepatitis c.
NZ702744A (en) D-amino acid compounds for liver disease
MX2020005054A (en) Combination of two antivirals for treating hepatitis c.
MY160130A (en) Hepatitis c virus inhibitors
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
IN2014MN01547A (en)
MX2012003171A (en) Novel macrocyclic inhibitors of hepatitis c virus replication.
MX2010008148A (en) Methods of treating viral infections.
MX2010001416A (en) Compounds for the treatment of hepatitis c.
WO2010085091A3 (en) Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
MX2020011107A (en) Glycosidase regimen for treatment of infectious disease.
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
WO2012006550A3 (en) Methods and compositions for treatment of lipogenic virus related conditions
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
MX2014014878A (en) Combination of therapeutic agents for treating hcv infection.
PH12012501303A1 (en) Compositions and methods for treating hepatitis b virus infection
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
ES2572355A2 (en) Combination of adf for use in the treatment of hcv (Machine-translation by Google Translate, not legally binding)
UA104754C2 (en) Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis c, liver fibrosis and impaired liver function